Drug development is changing as scientific advances create new ways to evaluate the safety of medicines before they reach human clinical trials. For many years, animal studies have been an important part of nonclinical drug development. Today, however, researchers and regulators are exploring alternative methods that may provide more human-relevant information while reducing reliance on animal testing. This shift is particularly important for pharmaceutical and biotechnology companies operating in FDA-regulated industries. Organizations must understand not only the scientific potential of emerging technologies but also how these methods fit into regulatory expectations. As the FDA advances its efforts to encourage scientifically appropriate alternatives, understanding the future of nonclinical testing has become an important consideration for drug developers, toxicologists, and regulatory professionals.

Why Is the FDA Reconsidering Traditional Nonclinical Testing?

Animal studies have historically helped researchers identify potential toxic effects, evaluate biological responses, and assess risks before administering an investigational drug to humans. These studies continue to play a role in many development programs, but they also have limitations. Animal biology does not always accurately reflect human physiology. Differences in metabolism, immune responses, and organ function can affect how a substance behaves across species. Consequently, findings from animal studies may not always predict human responses reliably. In April 2025, the FDA announced a roadmap to reduce animal testing in preclinical safety studies, particularly for monoclonal antibodies and other drugs where scientifically appropriate alternatives can be used. The initiative reflects a broader interest in improving the relevance of nonclinical evidence and supporting the development of innovative testing methods. However, this transition does not mean that animal studies are no longer necessary in every situation. The appropriate testing strategy depends on the drug, its mechanism of action, the available scientific evidence, and the safety questions that must be addressed. For companies developing new therapies, understanding these distinctions is essential when planning nonclinical studies and preparing regulatory submissions.

Alternatives to Animal Testing: Emerging Scientific Approaches

Advances in biotechnology, computational science, and human cell research are expanding the range of methods available for evaluating drug safety. These approaches are often described as New Approach Methodologies (NAMs). Their suitability depends on the intended application, the quality of the supporting evidence, and the limitations of each method.

Human cell-based testing

Human cells can be used to investigate how a drug affects specific cellular functions and biological pathways. These assays may help identify toxicity signals and provide insights into mechanisms that are relevant to human health.

Organoids and organ-on-a-chip systems

Organoids are three-dimensional structures that reproduce selected characteristics of human tissues or organs. Organ-on-a-chip technologies use engineered systems to model aspects of organ function and, in some cases, interactions between tissues. Depending on the application, these technologies may help researchers investigate drug responses that conventional models do not fully capture.

Computational models and artificial intelligence

Computational tools can analyze biological data, predict potential toxicity, and identify patterns associated with adverse effects. Artificial intelligence may also support the interpretation of complex datasets. Nevertheless, predictions must be evaluated for reliability, limitations, and applicability to the specific drug or biological system being studied.

Integrated testing strategies

Rather than relying on one method, researchers may combine information from several complementary approaches. Integrating laboratory assays, computational predictions, and existing scientific evidence can help build a more comprehensive understanding of potential risks.

These technologies offer promising opportunities, but they should not be treated as automatic replacements for every traditional study. Their value depends on whether they adequately address the relevant scientific and regulatory questions.

Nonclinical Safety Assessment: What Companies Need to Consider

A robust Nonclinical Safety Assessment remains essential for identifying potential risks before a medicine enters clinical development or progresses to later stages. As alternative testing methods become more widely explored, companies must determine whether their selected approaches provide sufficient evidence for the intended regulatory purpose. One important consideration is scientific validity. Organizations should evaluate whether a method is suitable for its intended use, whether its results are reproducible, and whether the findings can meaningfully inform human safety decisions. Another consideration is the interpretation of results. A promising outcome from a cell-based assay or computational model does not necessarily establish that a drug is safe. Researchers must consider what the method can demonstrate, what it cannot establish, and whether additional evidence is needed to address remaining uncertainties. Documentation is equally important. Companies should maintain clear records explaining the rationale for selecting a method, the procedures followed, the results obtained, and the limitations identified. These records help support scientific conclusions and provide a transparent basis for regulatory review. Early planning is also valuable. Evaluating alternative approaches during the initial stages of development may help organizations identify suitable methods, anticipate evidence gaps, and reduce the risk of unexpected delays.

Understanding FDA Drug Development Regulations

Emerging testing technologies must be considered within the broader framework of FDA Drug Development Regulations. Scientific innovation alone does not guarantee that a particular method will satisfy regulatory expectations. For sponsors preparing an Investigational New Drug (IND) application, the nonclinical evidence should be appropriate to the product and sufficient to support the proposed clinical investigation. The type and extent of information needed will depend on factors such as the drug’s characteristics, its intended use, the available data, and the potential risks to participants. Companies considering alternatives to traditional animal studies should therefore assess how their proposed methods address the relevant safety questions. They should also review applicable FDA guidance and consider seeking regulatory feedback when the acceptability of a proposed approach is uncertain. This is particularly important for complex products, including biologics, where species-specific biological activity may affect the relevance of traditional models and the interpretation of alternative testing results. Regulatory teams, nonclinical scientists, and drug development leaders should work together to evaluate these decisions. A coordinated approach can help ensure that scientific evidence, development objectives, and regulatory planning remain aligned. Importantly, the FDA’s evolving approach should not be interpreted as blanket approval for replacing all animal studies. Requirements and expectations must be assessed in the context of the specific product and development program.

How Companies Can Prepare for the Changing Landscape

Organizations can take several practical steps to prepare for developments in nonclinical testing. First, monitor FDA announcements and relevant guidance to understand how regulatory expectations are evolving. Second, evaluate emerging testing technologies based on their intended use rather than adopting them simply because they are new. Third, involve regulatory professionals early when considering changes to an established testing strategy. Companies should also identify evidence gaps, maintain traceable documentation, and ensure that scientific conclusions reflect both the strengths and limitations of the methods used. Training is another important consideration. Regulatory Affairs professionals, toxicologists, quality teams, and research scientists need a shared understanding of how alternative methods may affect development planning and regulatory submissions. By taking these steps, organizations can evaluate new opportunities without losing sight of their fundamental responsibility to demonstrate an appropriate level of safety.

Looking Ahead: A More Human-Relevant Approach to Drug Development

The future of nonclinical testing will likely involve a combination of established methods and emerging technologies. Human cell-based assays, organ-on-a-chip systems, computational models, and other New Approach Methodologies may help researchers generate more relevant evidence and reduce animal use where scientifically justified. For FDA-regulated companies, the challenge is to understand when these methods are appropriate, how their results should be interpreted, and what evidence is needed to support regulatory decisions. A thoughtful approach to innovation, supported by sound science and careful regulatory planning, can help organizations navigate this evolving landscape while maintaining patient safety as the central priority.